Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Dermatology

Welcome to Your DFSP Guide: Understanding Your Diagnosis

At a Glance

Dermatofibrosarcoma protuberans (DFSP) is a rare but highly treatable, slow-growing skin cancer. Unlike many sarcomas, classic DFSP rarely spreads to distant organs. The main risk is the tumor growing back in the same spot, making complete surgical removal by a specialist essential.

Hearing the word “sarcoma” is naturally frightening. However, it is important to know that Dermatofibrosarcoma protuberans (DFSP) is very different from the aggressive cancers most people associate with that term [1][2]. DFSP is a rare, slow-growing skin cancer that develops in the deep layers of the skin [3][1]. While it is technically a sarcoma—a type of cancer that begins in the body’s connective tissues—classic DFSP is considered a low-grade malignancy, meaning it grows slowly and rarely spreads to other parts of the body [3][4].

Understanding the Rarity

DFSP is exceptionally rare. Medical registries show that it affects only about 3 to 5 people out of every million each year [5][6]. Because it is so uncommon, many general practitioners or family doctors may never have seen a case in their entire career [7][6]. If your doctor seems unfamiliar with the details of your diagnosis, it is not a reflection of their skill, but rather the extreme rarity of the condition [8].

Three Stabilizing Facts for Your Diagnosis

When you are first diagnosed, the following facts can help anchor your expectations and reduce anxiety:

  1. High Treatability: DFSP is highly treatable and has an excellent survival rate [9][5]. When the tumor is removed completely with clear margins, the long-term outlook is very positive [10][11].
  2. Low Risk of Spreading: Unlike many other sarcomas, classic DFSP has a very low metastatic potential—the likelihood of the cancer traveling to distant organs like the lungs or liver [1][2]. It tends to stay “local,” meaning it primarily poses a risk only to the area of skin where it first appeared [2].
  3. Slow Growth Pattern: This is not a “fast-moving” cancer. DFSP often presents as a painless lump that may have been present for years before being diagnosed [12][13]. This slow growth usually allows you the time to seek out a specialist and make an informed treatment plan without rushing into emergency surgery [14].

Why DFSP is Different from Other Sarcomas

The term “sarcoma” covers a wide range of diseases, many of which can be quite aggressive. It is crucial to differentiate classic DFSP from these other types because the treatment approach and the risks are significantly different [1][4].

In most sarcomas, doctors are highly concerned about the cancer spreading through the bloodstream [4]. In classic DFSP, the primary challenge is not distant spread, but local recurrence—the tendency for the cancer to grow back in the same spot if even a tiny microscopic piece is left behind after surgery [15][11]. Because DFSP grows like “tentacles” or roots beneath the skin, specialized surgical techniques like Mohs micrographic surgery are often used to ensure every bit of the tumor is removed [10][15].

The Importance of Specialist Care

Because DFSP is so rare and its growth pattern is so unique, the quality of the initial surgery is the most important factor in your recovery [10]. Seeking care from a team that includes a dermatologic surgeon (especially one trained in Mohs surgery) or a sarcoma specialist ensures that your treatment is tailored to the specific way DFSP behaves [10][11][7]. This specialized approach significantly reduces the chance of the tumor coming back in the future [10][15].

Common questions in this guide

What is Dermatofibrosarcoma protuberans (DFSP)?
DFSP is a rare, slow-growing skin cancer that develops in the deep layers of the skin. While it is classified as a sarcoma, it is considered a low-grade malignancy because it rarely spreads to distant organs.
Does DFSP spread quickly?
No, classic DFSP is not a fast-moving cancer. It often presents as a painless lump that may grow very slowly over several years before being formally diagnosed, giving you time to find a specialist.
What is the main risk with a DFSP diagnosis?
The primary challenge with classic DFSP is local recurrence, meaning the tumor can grow back in the exact same spot if any microscopic pieces are left behind during surgery.
How is DFSP treated?
DFSP is highly treatable through surgery. Because the tumor grows with root-like tentacles beneath the skin, specialized techniques like Mohs micrographic surgery are often used to ensure every piece is completely removed.
Should I see a specialist for my DFSP diagnosis?
Yes, because DFSP affects only 3 to 5 people out of every million each year, many doctors have never seen a case. Consulting a specialized dermatologic surgeon or a sarcoma specialist is the best way to ensure the tumor is completely removed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my pathology report, do I have 'classic' DFSP or the 'fibrosarcomatous' variant?
  2. 2.How many cases of DFSP have you or this clinic treated in the past year?
  3. 3.Is Mohs micrographic surgery an option for my specific tumor, and if not, why?
  4. 4.What specific steps will be taken to ensure the tumor is completely removed during my surgery?
  5. 5.Given the rarity of this condition, is there a sarcoma specialist or a multidisciplinary team you recommend I consult?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Guidelines for Diagnosis and Treatment of Cutaneous Sarcomas: Dermatofibrosarcoma Protuberans.

    Llombart B, Serra C, Requena C, et al.

    Actas dermo-sifiliograficas 2018; (109(10)):868-877 doi:10.1016/j.ad.2018.05.006.

    PMID: 30539729
  2. 2

    Wide local excision vs. Mohs Tübingen technique in the treatment of dermatofibrosarcoma protuberans: a two-centre retrospective study and literature review.

    Veronese F, Boggio P, Tiberio R, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(12)):2069-2076 doi:10.1111/jdv.14378.

    PMID: 28573714
  3. 3

    Relapse in dermatofibrosarcoma protuberans: A histological and molecular analysis.

    Molina AS, Duprat Neto JP, Bertolli E, et al.

    Journal of surgical oncology 2018; (117(5)):845-850 doi:10.1002/jso.25039.

    PMID: 29509956
  4. 4

    Dermatofibrosarcoma Protuberans.

    Allen A, Ahn C, Sangüeza OP

    Dermatologic clinics 2019; (37(4)):483-488 doi:10.1016/j.det.2019.05.006.

    PMID: 31466588
  5. 5

    Incidence and Survival Outcomes of Dermatofibrosarcoma Protuberans From 2000 to 2020: A Population-Based Retrospective Cohort Analysis.

    Xiong DD, Bordeaux JS

    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2023; (49(12)):1096-1103 doi:10.1097/DSS.0000000000004018.

    PMID: 37962980
  6. 6

    Dermatofibrosarcoma Protuberans: The role of tissue expansion in reconstructive surgery of the scalp.

    Maguire R, Nikolorakos D, Lam A

    International journal of surgery case reports 2016; (19()):137-9.

    PMID: 26764887
  7. 7

    Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline.

    Saiag P, Grob JJ, Lebbe C, et al.

    European journal of cancer (Oxford, England : 1990) 2015; (51(17)):2604-8.

    PMID: 26189684
  8. 8

    Review of the medical literature and assessment of current utilization patterns regarding the use of two common fluorescence in situ hybridization assays in the diagnosis of dermatofibrosarcoma protuberans and clear cell sarcoma.

    Linos K, Kozel JA, Hurley MY, Andea AA

    Journal of cutaneous pathology 2018; (45(12)):905-913 doi:10.1111/cup.13345.

    PMID: 30155908
  9. 9

    Survival Outcomes and Prognostic Factors of Dermatofibrosarcoma Protuberans: A Population-Based Retrospective Cohort Analysis.

    Chen S, Xiong L, Zhao L, et al.

    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2023; (49(9)):825-831 doi:10.1097/DSS.0000000000003853.

    PMID: 37384896
  10. 10

    Dermatofibrosarcoma Protuberans Re-excision and Recurrence Rates in the Netherlands Between 1989 and 2016.

    van Lee CB, Kan WC, Gran S, et al.

    Acta dermato-venereologica 2019; (99(12)):1160-1165 doi:10.2340/00015555-3287.

    PMID: 31410492
  11. 11

    Treatment of dermatofibrosarcoma of the head and neck with Mohs surgery with paraffin sections.

    González A, Etchichury D, Rivero JM, Adamo L

    Journal of plastic, reconstructive & aesthetic surgery : JPRAS 2021; (74(5)):1061-1070 doi:10.1016/j.bjps.2020.10.062.

    PMID: 33317985
  12. 12

    A Rare Case of Dermatofibrosarcoma in a Pediatric Patient.

    Martinez PF, Richardson S, Bakovic M, et al.

    Plastic and reconstructive surgery. Global open 2024; (12(1)):e5546 doi:10.1097/GOX.0000000000005546.

    PMID: 38264448
  13. 13

    [A tumour mistaken for a scar].

    van den Brand AC, Erceg A

    Nederlands tijdschrift voor geneeskunde 2017; (161()):D707.

    PMID: 28421972
  14. 14

    S1-Leitlinie Dermatofibrosarcoma protuberans (DFSP) - Update 2018.

    Ugurel S, Kortmann RD, Mohr P, et al.

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2019; (17(6)):663-668 doi:10.1111/ddg.13849_g.

    PMID: 31241846
  15. 15

    Surgical management of dermatofibrosarcoma protuberans.

    Rust DJ, Kwinta BD, Geskin LJ, et al.

    Journal of surgical oncology 2023; (128(1)):87-96 doi:10.1002/jso.27258.

    PMID: 36999599

This page provides an educational overview of Dermatofibrosarcoma protuberans (DFSP). It is not a substitute for professional medical advice, and you should always consult your oncology team or dermatologist about your specific diagnosis.

Get notified when new evidence is published on Dermatofibrosarcoma protuberans.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.